Highlights and Quick Summary
- Annual Free Cash Flow Margin for 2021 was 0.0% (a NaN% decrease from previous year)
- Annual Free Cash Flow Margin for 2020 was 0.0% (a NaN% decrease from previous year)
- Annual Free Cash Flow Margin for 2019 was 0.0% (a NaN% decrease from previous year)
- Twelve month Free Cash Flow Margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
- Twelve month trailing Free Cash Flow Margin decreased by NaN% year-over-year
Trailing Free Cash Flow Margin for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% |
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Free Cash Flow Margin of Allena Pharmaceuticals, Inc.
Most recent Free Cash Flow Marginof ALNA including historical data for past 10 years.Interactive Chart of Free Cash Flow Margin of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Free Cash Flow Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | – | – | – | – | 0.0% |
| 2020 | – | – | – | – | 0.0% |
| 2019 | – | – | – | – | 0.0% |
| 2018 | – | – | – | – | 0.0% |
| 2017 | – | – | – | – | 0.0% |
| 2016 | – | – | – | – | 0.0% |
| 2015 | – | – | – | – | 0.0% |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.